Evolva AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evolva AG - overview
Established
2004
Location
Reinach, -, Switzerland
Primary Industry
Biotechnology
About
Based in Switzerland, Evolva Holding SA is engaged in developing and commercializing innovative natural ingredients for diverse industries, with a focus on sustainability and biosynthetic solutions. Evolva Holding SA is focused on the creation of natural ingredients, founded in 2004 in Reinach, Switzerland. The company was involved in 15 funding deals, with its most recent transaction being a Trade Sale to Lallemand Inc. for CHF 20 million on December 28, 2023.
Following this acquisition, Evolva AG will be delisted from the SIX Swiss Exchange. The company's leadership includes CEOs Christian Wichert and Matija Tomaskovic. Evolva Holding SA specializes in the development and commercialization of innovative natural ingredients across various sectors, particularly in food, beverages, and health. The company’s main products comprise biosynthetic flavors and fragrances, which enhance the sensory appeal of food and beverages while emphasizing sustainable practices.
Evolva serves a wide range of markets, including North America, Europe, and Asia, catering to food manufacturers, beverage companies, and personal care brands, and aims to fulfill the growing consumer demand for clean-label products focused on health and environmental responsibility. In the most recent year 2023, Evolva reported a revenue of CHF 4,629,128. 90, with an EBITDA of CHF -111,362,139. 30.
Following the recent acquisition by Lallemand Inc. , Evolva Holding SA aims to leverage the funds from the CHF 20 million deal to enhance its product offerings and expand into additional markets. The company will focus on launching new biosynthetic ingredients and increasing its presence in North America and Europe. The management anticipates that the strategic integration with Lallemand will facilitate further growth opportunities and market expansion.
Current Investors
Auriga Partners, Wellington Partners, Aravis
Primary Industry
Biotechnology
Sub Industries
Health Foods & Nutritional Supplements, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.evolva.com
Total Amount Raised
Subscriber access only
Evolva AG - timeline of key events

Evolva AG - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.